Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Research
[키워드] Alpha variant
anti-RBD
antibody
Antibody neutralization
AstraZeneca
B.1.1.7
B.1.617
B.1.617.2
binding
collected
convalescent individual
convalescent individuals
COVID-19
COVID-19 vaccine
Delta
delta variant
dominant
dose
epitope
examined
faster
France
immune evasion
include
India
individual
individual with COVID-19
individuals
inhibitory effect
less
Lineage
monoclonal antibodies
monoclonal antibody
Mutation
N-terminal domain
neutralization
Neutralizing
NTD
onset of symptom
other variants
Pfizer
RBD
Region
returned
SARS-CoV-2
SARS-CoV-2 variant
sensitivity
sera
Spike protein
Spread
spread to
strain
subtype
the receptor-binding domain
the SARS-CoV-2
the spike protein
the vaccine
titre
Vaccine
variants
[DOI] 10.1038/s41586-021-03777-9 [Article Type] Research
[DOI] 10.1038/s41586-021-03777-9 [Article Type] Research